Roche acquires Danish drugmaker in up to $450M deal

08/5/2014 | Reuters

Roche Holding agreed to pay $250 million in cash and up to $200 million in milestone fees to purchase Santaris Pharma, a Denmark-based biotech firm that specializes in developing RNA-targeted drugs. The acquisition is expected to be finalized this month.

View Full Article in:


Published in Brief: